Evidence map›Paper›PMID 33502304›Full record

ArticleMicrobial genomics2021

Exact mapping of Illumina blind spots in the

Samuel J Modlin, Cassidy Robinhold, Christopher Morrissey, Scott N Mitchell, Sarah M Ramirez-Busby, Tal Shmaya, Faramarz Valafar

Abstract read
In one paragraph

Article in Microbial genomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Variability in intrinsic drug tolerance inAntimicrobial agents and chemotherapy · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Loss of theScience advances · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Frontiers in microbiology · 2025
    Article
  15. Article
  16. Article
  17. Widespread loss-of-function mutations implicating preexisting resistance to new or repurposed anti-tuberculosis drugs.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2024
    Article
  18. Characteristic SNPs defining the major multidrug-resistantEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Samuel J ModlinLaboratory for Pathogenesis of Clinical Drug Resistance and Persistence, School of Public Health, San Diego State University, San Diego, CA 92182, USA.
Cassidy RobinholdLaboratory for Pathogenesis of Clinical Drug Resistance and Persistence, School of Public Health, San Diego State University, San Diego, CA 92182, USA.
Christopher MorrisseyLaboratory for Pathogenesis of Clinical Drug Resistance and Persistence, School of Public Health, San Diego State University, San Diego, CA 92182, USA.
Scott N MitchellLaboratory for Pathogenesis of Clinical Drug Resistance and Persistence, School of Public Health, San Diego State University, San Diego, CA 92182, USA.
Sarah M Ramirez-BusbyLaboratory for Pathogenesis of Clinical Drug Resistance and Persistence, School of Public Health, San Diego State University, San Diego, CA 92182, USA.
Tal ShmayaLaboratory for Pathogenesis of Clinical Drug Resistance and Persistence, School of Public Health, San Diego State University, San Diego, CA 92182, USA.
Faramarz ValafarLaboratory for Pathogenesis of Clinical Drug Resistance and Persistence, School of Public Health, San Diego State University, San Diego, CA 92182, USA.

Funding

Evolutionary and Functional Significance of Novel Mutations in MDR-XDR TBR01AI105185 · NIAID · SAN DIEGO STATE UNIVERSITY · PI VALAFAR, FARAMARZ · 2013 to 2021
$5.3M
Undetected Drug resistance and Tolerance in lesions of recurrent TBR01AI163202 · NIAID · SAN DIEGO STATE UNIVERSITY · PI VALAFAR, FARAMARZ · 2022 to 2025
$2.8M
NIAID NIH HHS R01 AI105185NIAID NIH HHS R01 AI163202
6 · The paper itself

Abstract

Whole-genome sequencing (WGS) is fundamental to

Indexed as

BiasGene LibraryGenome, BacterialHigh-Throughput Nucleotide SequencingHumansMycobacterium tuberculosisTuberculosisWhole Genome SequencingWorkflowblind spotscoverage biashomopolymersIlluminasequencingtuberculosis

Identifiers

PMID33502304
PMCPMC8190613

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.